Results from a Phase III registrational study suggest that ecopipam has potential as a first-in-class dopamine-1 receptor ...

The Phase III DIAMOND trial met both its primary and secondary endpoints of reducing tics in both children and adult patients ...

At the moment, attention is focused on candidates like Emalex Biosciences' ecopipam and Noema Pharma's gemlapodect, both in midstage clinical testing. An extraordinary meeting of shareholders is ...

A European Commission committee is recommending AbbVie's Rinvoq for treatment of giant cell arteritis following Phase 3 clinical trial results that showed efficacy and safety in the inflammatory ...

As usual, the Illinois General Assembly has a full plate of health care-related bills to consider this year, including legislation taking on pharmacy benefit managers, reproductive care and end-of ...

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

Story Jan. 10 - Shoreline Biosciences: The cell therapy biotech plans to let go of an undisclosed number of employees tied to a project with Gilead Sciences’ Kite Pharma. Story Jan. 9 - IGM ...

After hours: February 28 at 7:59:23 PM EST Loading Chart for ENVB ...